ImmunityBio's Legal Deadline and Record Revenue Collide

ImmunityBio faces a May 26 lead plaintiff deadline in a securities lawsuit over FDA warnings, even as its cancer drug ANKTIVA drives record quarterly revenue and gains key clinical endorsements.

A stark contrast defines ImmunityBio as a critical legal deadline approaches. The biotech firm faces a May 26 cutoff for investors to seek lead plaintiff status in a securities class action, even as it reports the strongest quarterly product revenue in its history. This divergence between mounting legal challenges and explosive commercial performance has left the market grappling with the stock's true valuation.

The lawsuit stems from a regulatory clash with the U.S. Food and Drug Administration. On March 13, 2026, the agency sent a warning letter to the company concerning promotional materials for its cancer immunotherapy, ANKTIVA. The FDA stated that a January 19 podcast titled "Is the FDA BLOCKING Life Saving Cancer Treatments?"—featuring Executive Chairman Patrick Soon-Shiong—and related television advertising misrepresented the drug's efficacy, violating federal law. The agency noted it had sent two prior letters to ImmunityBio's Altor BioScience subsidiary in September 2025 and January 2026 addressing similar violations. News of the March warning letter became public on March 24, triggering a single-day share price collapse of 21 percent to $7.42, erasing roughly $2 billion in market capitalization.

In response, ImmunityBio filed a comprehensive statement with the FDA on April 6, removed the podcast from its website, and confirmed the implicated TV commercial never aired. The company has pledged enhanced internal training and external regulatory oversight to prevent future missteps. Operationally, however, the business has never been stronger. Preliminary product revenue for the first quarter of 2026 hit approximately $44.2 million, a staggering 168 percent increase over the same period last year. The company ended the quarter with an estimated $380.9 million in cash and securities, providing substantial liquidity to support ANKTIVA's ongoing commercialization.

Legal pressure is intensifying. Multiple law firms, including Rosen Law Firm, Hagens Berman, and Kessler Topaz Meltzer & Check, have notified investors of the pending action, Douglas v. ImmunityBio, Inc. (2:26-cv-03261). The class period cited in the litigation runs from January 19 to March 24, 2026. Investors wishing to help shape the lawsuit must file a motion for lead plaintiff by May 26 in the U.S. District Court for the Central District of California.

Beyond the courtroom, the drug's commercial and clinical foundation appears solid. ANKTIVA is now approved in five regulatory regions encompassing approximately 34 countries. Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines now explicitly recommend ANKTIVA plus BCG for a specific form of bladder cancer. The company also has key near-term catalysts, including a planned regulatory submission for its QUILT-2.005 study and participation in investor events like the Morgan Stanley West Coast Biotech Bus Tour in early May and the AUA Annual Meeting 2026 in mid-May.

Since the March sell-off, the stock has shown tentative signs of recovery, gaining over six percent in a single session last Friday to close at $7.70 and advancing in six of the last ten trading days. The coming weeks will test whether the firm's record-breaking commercial execution can ultimately outweigh the significant legal overhang now facing its leadership.